“These data do suggest that [enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda)] is a viable treatment option for cisplatin-ineligible patients,” says Jonathan E. Rosenberg, MD.
“I think the take home message of this study is that there's work to do, and that our efforts in diversity, equity, and inclusion extends broadly beyond simply ensuring that we have the workforce to treat our diverse population, or that urologists are thinking critically and responsibly about the needs of our patients,” says Kevin Koo, MD, MPH.
“PSMA-PET imaging is something that from a clinical practice perspective is rapidly changing and evolving the field of prostate cancer,” says William P. Parker, MD.
“The leadership has really driven this program to be one of the best in the country,” says Casey Kowalik, MD.
“One thing that from the very beginning we talked about is how can we push this forward? How can we think outside the box and take this to the next level to make an impact for our patients?” says Katie Murray, DO, MS.
“There were no serious skin events that occurred on this study, which I think is a credit to the study team that worked with the investigators to manage the manage the toxicity and prevent serious skin reactions,” says Jonathan E. Rosenberg, MD.
“The main finding of the study was that, like…other clinical trial studies in the past, we also found that there was an over representation of non-Hispanic White patients in these trials, and a dramatic under representation of people traditionally and historically underrepresented in clinical trials and in medicine,” says Kevin Koo, MD, MPH.
“There is so much support and so much advocacy to work and create an equitable culture for women in this historically male-dominated field,” says Casey Kowalik, MD.
“A majority of the patients who were referred who had a catheter pre embolization are now catheter free,” says Kimberly Kocour, MD.
In this companion article, Brenda Heath, RN, discusses key challenges related to the use of leuprolide acetate and leuprolide mesylate from an organizational management perspective.
Daniel P. Petrylak, MD, discusses results of a post-hoc analysis of the phase 3 ARCHES trial examining outcomes with enzalutamide/ADT treatment intensification in patients with mHSPC and prior ADT based on patients’ baseline PSA level.
Stephen J. Freedland, MD, shares his thoughts on potential new uses for cabazitaxel in the prostate cancer paradigm.
“This concept of adding additional therapy early on is ready for primetime,” says Michael S. Cookson, MD, MMHC.
“We started in 2020 and so far, we’ve had 193 mentors and 126 mentees,” says Micha Cheng, MD, MPH, MS.
“[With] some folks, if you don't accurately risk stratify them, you miss your chance to really build that trust as a provider,” says Neil Mistry, MD, MPH.
The initial results from JAVELIN Bladder 100 supported the FDA approval of avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.
“There was about a 32.5% survival advantage for patients with that triple therapy,” says Michael S. Cookson, MD, MMHC.
In the fourth interview of the series, Brenda Heath, RN, shares expert insights into key factors related to nurse training on leuprolide administration, inventory management of the drug, and patient support programs.
Stephen J. Freedland, MD, discusses current practice patterns with cabazitaxel in prostate cancer and the potential to use the therapy earlier in treatment sequencing.
The pivotal CARD study compared cabazitaxel to androgen receptor pathway inhibitors in patients with previously treated metastatic castration-resistant prostate cancer.
“It’s hard to see yourself in a field when there are not that many residents or faculty that look like you,” says Micha Cheng, MD, MPH, MS.
Micha Yin-Zheng Cheng, MD, MPH, MS, discusses the background of the UCSF UReTER (UnderRepresented Trainees Entering Residency) Mentorship Program.
Danica May, MD, discusses positive feedback she has received from participants in the KU Department of Urology rotation.
"This device has been really well studied, and we have lots of data on it," says Andrew C. Peterson, MD, MPH.
In this companion article, Armine K. Smith, MD, reflects on the role of kidney-sparing approaches for LG UTUC and emphasizes the importance of patient-provider communication when making treatment decisions.
“We actually found that our calculator held up pretty well at different risk thresholds, especially when compared to the PCPT in terms of maintaining the same number of missed cancers, but cutting the number of biopsies that were not necessary nearly in half,” says Neil Mistry, MD, MPH.
“When it comes to encouraging patients to utilize this therapy the number 1 thing I say is that it is the most effective therapy out there on the market,” says Raveen Syan, MD.
“We still need better representation from the AUA national level on down to the section meeting. There is a positive push for that, but things are still in process,” says Danica May, MD.
“It’s always fun getting to interact with people from different programs and different areas and we want to make them feel as welcome as possible,” says Danica May, MD.
